Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 November 4, 2026 Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting Read more November 3, 2026 Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update Read more October 27, 2026 Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation Read more October 27, 2026 Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 Read more October 7, 2026 Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease Read more October 1, 2026 Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® Read more September 29, 2026 Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Read more September 28, 2026 Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate Read more September 3, 2026 Arvinas to Participate in Upcoming Investor Conferences Read more September 1, 2026 Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Read more
November 4, 2026 Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting Read more
November 3, 2026 Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update Read more
October 27, 2026 Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation Read more
October 27, 2026 Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 Read more
October 7, 2026 Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease Read more
October 1, 2026 Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® Read more
September 28, 2026 Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate Read more
